Skip to main content
. 2022 Sep;11(9):1497–1506. doi: 10.21037/gs-22-454

Table 2. Factors for being unvaccinated in participants.

Factors Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Age (years)
   <30 Ref. Ref.
   30–39 1.63 (0.39, 6.80) 0.503 0.88 (0.16, 4.75) 0.877
   40–49 1.70 (0.91, 3.19) 0.098 1.37 (0.65, 2.89) 0.405
   50–60 1.03 (0.58, 1.82) 0.916 1.12 (0.57, 2.21) 0.734
   >60 0.92 (0.52, 1.65) 0.789 1.09 (0.55, 2.16) 0.810
Current treatment
   NT Ref. Ref.
   ET 0.16 (0.10, 0.25) <0.001 0.51 (0.29, 0.89) 0.017
   Others 0.28 (0.19, 0.41) <0.001 0.68 (0.44, 1.07) 0.096
Time since surgery
   <1 year Ref. Ref.
   1–2 years 29.80 (16.86, 52.65) <0.001 22.49 (12.31, 41.10) <0.001
   2–5 years 9.25 (5.49, 15.59) <0.001 8.49 (4.98, 14.46) <0.001
   >5 years 1.93 (1.20, 3.08) 0.006 1.79 (1.11, 2.89) 0.017
Anxiety (GAD-2 ≥3) 2.07 (1.17, 3.67) 0.013 0.83 (0.38, 1.82) 0.649
Depression (PHQ-2 ≥3) 2.57 (1.46, 4.50) 0.001 2.48 (1.19, 5.15) 0.015

OR, odds ratio; CI, confidence interval; NT, not receiving a treatment; ET, only endocrine therapy (such as tamoxifen, toremifene, anastrozole, exemestane); Others, CT or TT or RT or CMT or ≥2 therapy methods; CT, chemotherapy; TT, HER2-targeted therapy (such as trastuzumab, pertuzumab, and pyrotinib, among others); RT, radiation therapy; CMT, Chinese medicine treatment; 1–2 years, including the second year after surgery; 2–5 years, the second year after surgery is not included; GAD-2, 2-item Generalized Anxiety Disorder scale; PHQ-2, 2-item Patient Health Questionnaire.